Clinical Treatment and Clinical Application Research Progress of Psoriasis and Intestinal Microbiota Dysbiosis

Psoriasis is a prevalent chronic inflammatory dermatosis. Recent evidence indicates a significant association between gut microbiota dysbiosis and its pathogenesis, potentially mediated through immunoinflammatory modulation and skin barrier integrity. This article systematically reviews the mechanisms linking gut microbiota to psoriasis, with emphasis on clinical treatment strategies targeting microbiota modulation-including probiotics, fecal microbiota transplantation (FMT), dietary interventions, and antibiotic therapies. However, current research exhibits notable limitations: most evidence derives from small-scale studies or animal models, lacking validation via large-scale clinical trials; microbiota-targeted interventions are poorly standardized, and the impact of individual variability on therapeutic outcomes remains unclear; the long-term safety of antibiotics and FMT requires further assessment. While summarizing existing advances, this review presents an evaluative overview to highlight research gaps and proposes future directions, such as integrated multi-omics studies, development of standardized therapeutic protocols, and exploration of personalized microbiota-based strategies, to innovate clinical management of psoriasis.